Record-Setting Deal For Pharmasset Expected To Boost Value Of Other HCV Biotechs
Executive Summary
The $11 billion Gilead plans to pay for Pharmasset dwarfs any prior deal for a clinical-stage biotech, and should be good news for other biotechs with hepatitis C candidates, like Inhibitex, Achillion and Idenix.